Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412562 | 0.89 | CYP4F2 (0.37) | HRH3SLC6A4PDE9ASLC22A12CYP4F2 | |
| SCHEMBL5423843 | 0.83 | ALDH1A1 (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL14722997 | 0.73 | RXRA (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21230708 | 0.73 | CYP4F2 (0.46) | PDE9ACYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30672085 | 0.72 | RXRA (0.55) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1208574 | 0.72 | RXRA (0.55) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL5413157 | 0.72 | ALDH1A1 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL5412575 | 0.72 | ALDH1A1 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL5412574 | 0.72 | ALDH1A1 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL767841 | 0.71 | RXRA (0.43) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | HRH3 1124/4885SLC6A4 4344/4885EPAS1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.